1
LMR Georgette's PMHNP Certification Exam V2
ACTUAL EXAM QUESTIONS AND ANSWERS
2026/2027 | ANCC PMHNP Board Certification |
100% Correct Verified Solutions | Pass
Guaranteed - A+ Graded
SECTION 1: Scientific Foundations & Advanced Physiology (Questions 1-25)
Q1: A 28-year-old patient with schizophrenia shows minimal response to risperidone.
Genetic testing reveals a CYP2D6 ultrarapid metabolizer status. Which neurotransmitter
pathway is primarily affected by this pharmacogenomic finding?
A. Dopamine metabolism via increased D2 receptor blockade [CORRECT] B. Serotonin
reuptake inhibition C. GABA receptor modulation D. Glutamate NMDA receptor antagonism
Correct Answer: A
Rationale: CYP2D6 is the primary enzyme responsible for metabolizing risperidone to its active
metabolite (9-hydroxyrisperidone). In ultrarapid metabolizers, the drug is cleared too quickly,
resulting in subtherapeutic plasma levels and insufficient D2 receptor blockade, which explains
the poor clinical response. This is a pharmacokinetic issue affecting dopaminergic
neurotransmission.
Distractor Analysis:
B: Serotonin reuptake is not the primary mechanism of risperidone; this describes SSRIs.
C: GABA modulation is relevant to benzodiazepines and some anticonvulsants, not
antipsychotic metabolism.
D: Glutamate NMDA antagonism is the mechanism of memantine and ketamine, not relevant to
CYP2D6 metabolism.
Q2: Which brain region demonstrates the most significant volume reduction in chronic
schizophrenia, as evidenced by longitudinal neuroimaging studies?
,2
A. Hippocampus B. Superior temporal gyrus [CORRECT] C. Cerebellum D. Occipital cortex
Correct Answer: B
Rationale: The superior temporal gyrus (particularly the left side) shows consistent volume
reductions in schizophrenia and correlates with severity of positive symptoms, especially
auditory hallucinations. This region contains Heschl's gyrus (primary auditory cortex) and is
critical for language processing. Progressive volume loss in this area is well-documented in
longitudinal studies.
Distractor Analysis:
A: Hippocampal volume reduction occurs but is more characteristic of depression, PTSD, and
neurodegenerative disorders.
B: CORRECT - Superior temporal gyrus shows the most consistent and significant volume
reduction specific to schizophrenia.
C: Cerebellar changes occur but are less prominent than temporal lobe findings.
D: Occipital cortex is relatively spared in schizophrenia compared to frontal and temporal
regions.
Q3: A patient with treatment-resistant depression undergoes PET imaging showing
decreased metabolic activity in the dorsolateral prefrontal cortex (DLPFC) and increased
activity in the subgenual anterior cingulate cortex (sgACC). Which neuromodulation
treatment directly targets this pathophysiological pattern?
A. Vagus nerve stimulation targeting the nucleus tractus solitarius B. Repetitive transcranial
magnetic stimulation (rTMS) to the left DLPFC [CORRECT] C. Deep brain stimulation of
the globus pallidus internus D. Electroconvulsive therapy with bifrontal electrode placement
Correct Answer: B
Rationale: The described pattern—hypoactive DLPFC and hyperactive sgACC—is the
established neurocircuitry model for major depression. High-frequency rTMS to the left DLPFC
increases cortical excitability in this region and indirectly normalizes sgACC activity through
fronto-limbic connectivity. This is FDA-approved for treatment-resistant depression.
Distractor Analysis:
A: VNS affects brainstem regions and has indirect effects; it doesn't specifically target the
DLPFC-sgACC circuit.
B: CORRECT - Left DLPFC rTMS directly addresses the pathophysiological pattern described.
,3
C: DBS for depression targets the sgACC or ventral capsule/ventral striatum, not the globus
pallidus (which is used for movement disorders).
D: ECT has generalized effects rather than specific circuit targeting; bifrontal placement is not
specific to DLPFC.
Q4: Which neurotransmitter system is primarily responsible for the therapeutic effects of
memantine in Alzheimer's disease?
A. Acetylcholinesterase inhibition B. Glutamate NMDA receptor modulation [CORRECT] C.
Dopamine D2 receptor antagonism D. Serotonin 5-HT3 receptor blockade
Correct Answer: B
Rationale: Memantine is a low-affinity, uncompetitive NMDA receptor antagonist that blocks
pathological glutamate excitotoxicity while preserving physiological NMDA function. This "fast-
off" kinetics differentiates it from high-affinity antagonists like ketamine and provides
neuroprotection in Alzheimer's disease.
Distractor Analysis:
A: This describes donepezil, rivastigmine, and galantamine—not memantine.
B: CORRECT - Memantine's unique NMDA receptor pharmacology provides symptomatic
benefit in moderate-to-severe Alzheimer's.
C: D2 antagonism is the mechanism of antipsychotics, not relevant to memantine.
D: 5-HT3 antagonism is seen in ondansetron and some atypical antipsychotics (e.g., clozapine),
not memantine.
Q5: A 6-year-old child presents with severe irritability, hyperactivity, and aggressive
outbursts. Genetic testing confirms a mutation in the MECP2 gene. Which
neurodevelopmental mechanism explains the psychiatric manifestations?
A. Excessive dopamine transporter function B. X-linked gene encoding methyl-CpG-binding
protein 2 affecting synaptic maturation [CORRECT] C. Serotonin synthesis enzyme
deficiency D. GABA-A receptor subunit mutation
Correct Answer: B
Rationale: MECP2 mutations cause Rett syndrome (classically in females, though variants
affect males). MECP2 is a transcriptional regulator critical for synaptic development and
, 4
maintenance. Mutations lead to impaired neuronal maturation, reduced dendritic complexity, and
altered synaptic plasticity, explaining the severe neurodevelopmental and behavioral symptoms.
Distractor Analysis:
A: Dopamine transporter issues are seen in ADHD medication mechanisms, not MECP2.
B: CORRECT - MECP2 is located on Xq28 and regulates genes essential for neuronal
development.
C: Serotonin synthesis defects cause different phenotypes (e.g., tryptophan hydroxylase
deficiencies).
D: GABA-A subunit mutations are associated with epilepsy syndromes, not Rett syndrome.
Q6: In the hypothalamic-pituitary-adrenal (HPA) axis, which finding is most characteristic
of chronic major depression?
A. Decreased corticotropin-releasing hormone (CRH) in the hypothalamus B. Elevated cortisol
with impaired negative feedback [CORRECT] C. Increased glucocorticoid receptor sensitivity
in the hippocampus D. Suppressed adrenal androgen production
Correct Answer: B
Rationale: Chronic depression is associated with HPA axis hyperactivity: elevated CRH,
increased ACTH, and hypercortisolemia. Critically, there is impaired negative feedback at the
level of the hippocampus and pituitary (glucocorticoid resistance), preventing normal cortisol
suppression. This is the basis for the dexamethasone suppression test and explains hippocampal
volume loss in chronic depression.
Distractor Analysis:
A: CRH is elevated, not decreased, in depression (particularly in melancholic features).
B: CORRECT - Hypercortisolemia with glucocorticoid resistance is the hallmark HPA finding.
C: Glucocorticoid receptor sensitivity is decreased (resistance), not increased.
D: Adrenal androgens (DHEA, DHEA-S) are often elevated in depression, not suppressed.
Q7: Which statement accurately describes the role of brain-derived neurotrophic factor
(BDNF) in psychiatric disorders?
A. BDNF levels are elevated in depression and normalized by antidepressant treatment B.
Decreased BDNF in hippocampus and prefrontal cortex contributes to depression
LMR Georgette's PMHNP Certification Exam V2
ACTUAL EXAM QUESTIONS AND ANSWERS
2026/2027 | ANCC PMHNP Board Certification |
100% Correct Verified Solutions | Pass
Guaranteed - A+ Graded
SECTION 1: Scientific Foundations & Advanced Physiology (Questions 1-25)
Q1: A 28-year-old patient with schizophrenia shows minimal response to risperidone.
Genetic testing reveals a CYP2D6 ultrarapid metabolizer status. Which neurotransmitter
pathway is primarily affected by this pharmacogenomic finding?
A. Dopamine metabolism via increased D2 receptor blockade [CORRECT] B. Serotonin
reuptake inhibition C. GABA receptor modulation D. Glutamate NMDA receptor antagonism
Correct Answer: A
Rationale: CYP2D6 is the primary enzyme responsible for metabolizing risperidone to its active
metabolite (9-hydroxyrisperidone). In ultrarapid metabolizers, the drug is cleared too quickly,
resulting in subtherapeutic plasma levels and insufficient D2 receptor blockade, which explains
the poor clinical response. This is a pharmacokinetic issue affecting dopaminergic
neurotransmission.
Distractor Analysis:
B: Serotonin reuptake is not the primary mechanism of risperidone; this describes SSRIs.
C: GABA modulation is relevant to benzodiazepines and some anticonvulsants, not
antipsychotic metabolism.
D: Glutamate NMDA antagonism is the mechanism of memantine and ketamine, not relevant to
CYP2D6 metabolism.
Q2: Which brain region demonstrates the most significant volume reduction in chronic
schizophrenia, as evidenced by longitudinal neuroimaging studies?
,2
A. Hippocampus B. Superior temporal gyrus [CORRECT] C. Cerebellum D. Occipital cortex
Correct Answer: B
Rationale: The superior temporal gyrus (particularly the left side) shows consistent volume
reductions in schizophrenia and correlates with severity of positive symptoms, especially
auditory hallucinations. This region contains Heschl's gyrus (primary auditory cortex) and is
critical for language processing. Progressive volume loss in this area is well-documented in
longitudinal studies.
Distractor Analysis:
A: Hippocampal volume reduction occurs but is more characteristic of depression, PTSD, and
neurodegenerative disorders.
B: CORRECT - Superior temporal gyrus shows the most consistent and significant volume
reduction specific to schizophrenia.
C: Cerebellar changes occur but are less prominent than temporal lobe findings.
D: Occipital cortex is relatively spared in schizophrenia compared to frontal and temporal
regions.
Q3: A patient with treatment-resistant depression undergoes PET imaging showing
decreased metabolic activity in the dorsolateral prefrontal cortex (DLPFC) and increased
activity in the subgenual anterior cingulate cortex (sgACC). Which neuromodulation
treatment directly targets this pathophysiological pattern?
A. Vagus nerve stimulation targeting the nucleus tractus solitarius B. Repetitive transcranial
magnetic stimulation (rTMS) to the left DLPFC [CORRECT] C. Deep brain stimulation of
the globus pallidus internus D. Electroconvulsive therapy with bifrontal electrode placement
Correct Answer: B
Rationale: The described pattern—hypoactive DLPFC and hyperactive sgACC—is the
established neurocircuitry model for major depression. High-frequency rTMS to the left DLPFC
increases cortical excitability in this region and indirectly normalizes sgACC activity through
fronto-limbic connectivity. This is FDA-approved for treatment-resistant depression.
Distractor Analysis:
A: VNS affects brainstem regions and has indirect effects; it doesn't specifically target the
DLPFC-sgACC circuit.
B: CORRECT - Left DLPFC rTMS directly addresses the pathophysiological pattern described.
,3
C: DBS for depression targets the sgACC or ventral capsule/ventral striatum, not the globus
pallidus (which is used for movement disorders).
D: ECT has generalized effects rather than specific circuit targeting; bifrontal placement is not
specific to DLPFC.
Q4: Which neurotransmitter system is primarily responsible for the therapeutic effects of
memantine in Alzheimer's disease?
A. Acetylcholinesterase inhibition B. Glutamate NMDA receptor modulation [CORRECT] C.
Dopamine D2 receptor antagonism D. Serotonin 5-HT3 receptor blockade
Correct Answer: B
Rationale: Memantine is a low-affinity, uncompetitive NMDA receptor antagonist that blocks
pathological glutamate excitotoxicity while preserving physiological NMDA function. This "fast-
off" kinetics differentiates it from high-affinity antagonists like ketamine and provides
neuroprotection in Alzheimer's disease.
Distractor Analysis:
A: This describes donepezil, rivastigmine, and galantamine—not memantine.
B: CORRECT - Memantine's unique NMDA receptor pharmacology provides symptomatic
benefit in moderate-to-severe Alzheimer's.
C: D2 antagonism is the mechanism of antipsychotics, not relevant to memantine.
D: 5-HT3 antagonism is seen in ondansetron and some atypical antipsychotics (e.g., clozapine),
not memantine.
Q5: A 6-year-old child presents with severe irritability, hyperactivity, and aggressive
outbursts. Genetic testing confirms a mutation in the MECP2 gene. Which
neurodevelopmental mechanism explains the psychiatric manifestations?
A. Excessive dopamine transporter function B. X-linked gene encoding methyl-CpG-binding
protein 2 affecting synaptic maturation [CORRECT] C. Serotonin synthesis enzyme
deficiency D. GABA-A receptor subunit mutation
Correct Answer: B
Rationale: MECP2 mutations cause Rett syndrome (classically in females, though variants
affect males). MECP2 is a transcriptional regulator critical for synaptic development and
, 4
maintenance. Mutations lead to impaired neuronal maturation, reduced dendritic complexity, and
altered synaptic plasticity, explaining the severe neurodevelopmental and behavioral symptoms.
Distractor Analysis:
A: Dopamine transporter issues are seen in ADHD medication mechanisms, not MECP2.
B: CORRECT - MECP2 is located on Xq28 and regulates genes essential for neuronal
development.
C: Serotonin synthesis defects cause different phenotypes (e.g., tryptophan hydroxylase
deficiencies).
D: GABA-A subunit mutations are associated with epilepsy syndromes, not Rett syndrome.
Q6: In the hypothalamic-pituitary-adrenal (HPA) axis, which finding is most characteristic
of chronic major depression?
A. Decreased corticotropin-releasing hormone (CRH) in the hypothalamus B. Elevated cortisol
with impaired negative feedback [CORRECT] C. Increased glucocorticoid receptor sensitivity
in the hippocampus D. Suppressed adrenal androgen production
Correct Answer: B
Rationale: Chronic depression is associated with HPA axis hyperactivity: elevated CRH,
increased ACTH, and hypercortisolemia. Critically, there is impaired negative feedback at the
level of the hippocampus and pituitary (glucocorticoid resistance), preventing normal cortisol
suppression. This is the basis for the dexamethasone suppression test and explains hippocampal
volume loss in chronic depression.
Distractor Analysis:
A: CRH is elevated, not decreased, in depression (particularly in melancholic features).
B: CORRECT - Hypercortisolemia with glucocorticoid resistance is the hallmark HPA finding.
C: Glucocorticoid receptor sensitivity is decreased (resistance), not increased.
D: Adrenal androgens (DHEA, DHEA-S) are often elevated in depression, not suppressed.
Q7: Which statement accurately describes the role of brain-derived neurotrophic factor
(BDNF) in psychiatric disorders?
A. BDNF levels are elevated in depression and normalized by antidepressant treatment B.
Decreased BDNF in hippocampus and prefrontal cortex contributes to depression
